Capture Intelligence

Assembling intelligence…

◎ CONTRACT VEHICLE SITREP // UNCLASSIFIED // COMPANY PROPRIETARY // SAM.GOV // USASPENDING // GAO

Public preview: the holder roster and vehicle ceiling are free. A free account unlocks more; subscriptions are coming soon.Sign up free Pricing

◎ Contract Vehicle SITREP

Analysis derived from public records, not verified fact. Verify independently before relying on it.

36F79722D0169

Incumbent-intelligence read on this vehicle: who holds it, how the money has moved, and where the option runway opens the next recompete.

Multi-award vehicle (MAC / GWAC / Schedule) (FSS) · Multiple award · Department of Veterans Affairs, NAC FEDERAL SUPPLY SCHEDULE (36F797)

$55M ceiling6 holdersNAICS 325412

§1

Bottom Line Up Front

▪What this is. 36F79722D0169 is a multi-award vehicle (mac / gwac / schedule) (FSS) issued by Department of Veterans Affairs, NAC FEDERAL SUPPLY SCHEDULE (36F797), solicitation 65 I B, a multiple award vehicle with a combined ceiling of $55M, held by 6 primes on the public record.
▪The money. Funded totals against the $55M ceiling, split by prime, are a subscription read; the holder roster is on the public record below.
▪Recompete timing. No period-of-performance end is on record for this vehicle; recompete timing is not determined.
▪The read. For a challenger: the holder roster below is the field to beat, and the option runway sets the earliest realistic entry point. For an incumbent: defend the funded share and the option ladder now, and watch for deobligations or thinning competition as an early signal of a scope change.

§2

Entity Baseline

What this vehicle is and its scale, from the public contract record. Raw identifiers live here and in Sourcing; the body refers to the vehicle and its holders by name.

Vehicle	36F79722D0169
Type	Multi-award vehicle (MAC / GWAC / Schedule) (FSS)
Award structure	Multiple award
Awarding agency / office	Department of Veterans Affairs, NAC FEDERAL SUPPLY SCHEDULE (36F797)
Combined ceiling	$55M
Funded to date	available with subscription
Period through	n/a
Base solicitation	65 I B
NAICS / PSC	325412 · PSC 6505
Vehicle ID

§3

Incumbent Baseline · Prime Roster

Every prime holder on the vehicle, from public contract award records. These are the incumbents a challenger displaces and the field most likely to defend.

Prime	Identifiers	Ceiling
RICHMOND PHARMACEUTICALS, INC.	vehicle 36F79724D0061 UEI SQBGG7CRT1C5	$39,000,000
HLS THERAPEUTICS INC	vehicle 36F79722D0169 UEI ME8TM7LFPS76	$13,848,500
SILVERGATE PHARMACEUTICALS INC	vehicle V797D40319 UEI JKA9DWNNHHB1	$1,096,120
THERAKOS LLC	vehicle 36F79721D0078 UEI KGLHB9TM34M5	$750,000
ACACIA PHARMA, INC.	vehicle 36F79721D0182 UEI CXXMWSCSBN49	$225,000

§4

Money Movement, Orders & Vehicle Intelligence

🔒 Funded share, task orders, and corporate history

Funded position by prime, the fiscal-year obligation curve, order-level detail with options and deobligations, novation history, competition intensity, teaming, and how this buying office competes the category overall. Paid plans read the contract action records.

Upgrade to unlock

§5

Agencies & Offices Ordering Off It

Who actually places orders under this vehicle, from public contract award records.

Agencies

No agencies with recorded orders under this vehicle yet.

Offices

No offices with recorded orders under this vehicle yet.

§6

Key Analytic Assessments

DETERMINEDHigh confidence
The incumbent roster is on the public record. This vehicle is a 6-holder multiple-award family with a combined ceiling of $55M, held by RICHMOND PHARMACEUTICALS, INC., HLS THERAPEUTICS INC, SILVERGATE PHARMACEUTICALS INC, THERAKOS LLC, ACACIA PHARMA, INC., TITAN PHARMACEUTICALS INC.
MUST-CHECKintelligence gap
Successor vehicle structure. Whether this vehicle re-competes as a standalone follow-on or the requirement migrates onto a different GWAC or Schedule path is not established on the public record.
MUST-CHECKintelligence gap
Teaming coverage is partial. First-tier subcontract reporting is required only above a dollar threshold and many primes under-report, so any teaming picture is a floor, not the full bench.

§7

Intelligence Gaps & Outlook

What this SITREP could not determine from the public record, consolidated. Each is an action for the capture team.

▸Exact option end and extensions. the option ladder shown reflects exercised actions on record; the contractual final option end date and any bilateral extensions are a solicitation-document pull, not a public contract-action fact.
▸Successor vehicle structure. whether this scope re-competes as a standalone follow-on, a new GWAC lane, or an existing Schedule path is unposted until the buying office publishes it.
▸Past-performance attribution on novated seats. how a recompete evaluation would score incumbency acquired by novation is an RFP and legal question, not a settled public-record fact.
▸Teaming beyond the reported floor. first-tier subcontract reporting is thresholded and under-reported; mentor-protege and joint-venture ties are not in these records.
▸Current SAM size and status of every holder. business size and socioeconomic standing reflect each holder's registration on file; confirm the current size rep for any specific target NAICS before relying on set-aside eligibility.

INFERRED

§8

Sourcing

All findings derive from public federal records, as of Sat Aug 01. Raw identifiers live here and in the Entity Baseline.

Federal contract award records (FPDS / USASpending), vehicle 36F79722D0169, contract ID CONT_IDV_36F79722D0169_3600, Department of Veterans Affairs, NAC FEDERAL SUPPLY SCHEDULE (36F797), NAICS 325412, PSC 6505, combined ceiling $55M.
Federal contract action records (FPDS / USASpending), incumbent holders: RICHMOND PHARMACEUTICALS, INC. (contract 36F79724D0061, UEI SQBGG7CRT1C5, ceiling $39M); HLS THERAPEUTICS INC (contract 36F79722D0169, UEI ME8TM7LFPS76, ceiling $14M); SILVERGATE PHARMACEUTICALS INC (contract V797D40319, UEI JKA9DWNNHHB1, ceiling $1M); THERAKOS LLC (contract 36F79721D0078, UEI KGLHB9TM34M5, ceiling $750K); ACACIA PHARMA, INC. (contract 36F79721D0182, UEI CXXMWSCSBN49, ceiling $225K); TITAN PHARMACEUTICALS INC (contract 36F79720D0051, UEI E6BMASC5QBS9, ceiling $225K).

◎ CONTRACT VEHICLE SITREP // UNCLASSIFIED // COMPANY PROPRIETARY

Investigate|Radar|Illustrative intelligence from public data; supports, does not replace, your capture decision. The live record on SAM and USASpending always governs.